Duopharma Biotech Berhad Balance Sheet Health
Financial Health criteria checks 4/6
Duopharma Biotech Berhad has a total shareholder equity of MYR696.0M and total debt of MYR524.5M, which brings its debt-to-equity ratio to 75.4%. Its total assets and total liabilities are MYR1.4B and MYR656.9M respectively. Duopharma Biotech Berhad's EBIT is MYR89.8M making its interest coverage ratio 4.6. It has cash and short-term investments of MYR260.4M.
Key information
75.4%
Debt to equity ratio
RM 524.50m
Debt
| Interest coverage ratio | 4.6x |
| Cash | RM 260.42m |
| Equity | RM 696.05m |
| Total liabilities | RM 656.88m |
| Total assets | RM 1.35b |
Recent financial health updates
These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively
Oct 21
Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly
May 22Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly
Feb 12Recent updates
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005
Aug 27Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018
Apr 04Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price
Feb 17These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively
Oct 21Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005
Aug 18Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Aug 07Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year
Mar 28Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Mar 27We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings
Nov 26Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021
Nov 25Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005
Aug 20Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly
May 22Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend
Apr 13A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Mar 14Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly
Feb 12Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?
Jan 28
Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?
Jan 12Financial Position Analysis
Short Term Liabilities: DPHARMA's short term assets (MYR725.3M) exceed its short term liabilities (MYR167.6M).
Long Term Liabilities: DPHARMA's short term assets (MYR725.3M) exceed its long term liabilities (MYR489.3M).
Debt to Equity History and Analysis
Debt Level: DPHARMA's net debt to equity ratio (37.9%) is considered satisfactory.
Reducing Debt: DPHARMA's debt to equity ratio has increased from 52% to 75.4% over the past 5 years.
Debt Coverage: DPHARMA's debt is not well covered by operating cash flow (17.9%).
Interest Coverage: DPHARMA's interest payments on its debt are well covered by EBIT (4.6x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 12:39 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Duopharma Biotech Berhad is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Khir Goh | AmInvestment Bank Berhad |
| Kok Chee | AmInvestment Bank Berhad |
| Hsien Jin Lam | CGS International |